Recombinant granulocyte colony stimulating factor (filgrastim) of prolonged action: Optimization of conditions for extraction and purification from inclusion bodies

被引：0
作者：
N. V. Kononova
A. V. Yakovlev
A. M. Zhuravko
N. N. Pankeev
S. V. Minaev
A. I. Bobruskin
V. A. Mart’yanov
机构：
[1] Russian Pharmaceutical Company ZAO Masterklon,
来源：
Russian Journal of Bioorganic Chemistry | 2014年 / 40卷
关键词：
polyethylene glycol (PEG); granulocyte colony-stimulating factor (GCSF); filgrastim; febrile neutropenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A unified technology platform for the production of two medical products with nonprolonged and prolonged action on the basis of the recombinant human granulocyte colony-stimulating factor (filgrastim) was developed. The production cost for the previously developed domestic medical product was reduced by the unified technology. Moreover, the introduction of an additional step for the PEGylation of the recombinant granulocyte colony stimulating factor to the technological line allowed the start of the production of a new generation of the medical product and standardization of the documenting procedure for the technological process in accordance with GMP requirements.
引用
收藏
页码：507 / 515
页数：8
相关论文
共 96 条
[1]  
Ptushkin VV(1999)undefined Antibiotiki Khimioter. 44 31-33
[2]  
Minenko SV(2006)undefined Prakt. Onkol. 7 69-76
[3]  
Orlova RV(2000)undefined Int. J. Immunopharmacol. 22 557-566
[4]  
Chubenko VA(1988)undefined Br. J. Cancer 58 64-69
[5]  
Bialasiewicz P(1989)undefined Proc. NatL. Acad. Sci. USA 86 9499-9503
[6]  
Stolarek R(1986)undefined EMBO J. 5 871-876
[7]  
Wejner P(1992)undefined Lancet 339 640-644
[8]  
Piasecka G(1996)undefined Blood 88 1907-1929
[9]  
Dutkiewicz B(1994)undefined Eur. J. Cancer 30A 12-14
[10]  
Mikucki J(1994)undefined Eur. J. Cancer 30A 7-11
12345678910